Lisata Therapeutics, Inc. (LSTA) announced on Tuesday that it has received an orphan drug designation from the FDA for LSTA1, the company's primary product candidate, to treat osteosarcoma, a rare form of bone cancer that can occur in young individuals.
The orphan drug designation is set to allow a seven-year exclusive marketing period after approval, along with exemption from user fees and eligibility for tax credits for applicable clinical trials.
LSTA1 has previously obtained orphan drug designation for pancreatic cancer in the U.S. and Europe, as well as for glioblastoma multiforme and osteosarcoma in the U.S. Moreover, it secured a Fast Track designation for pancreatic cancer and, on March 21, 2024, a Rare Pediatric Disease designation for osteosarcoma from the FDA.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.